Tenaya Therapeutics (TNYA) EBITDA (2020 - 2026)

Tenaya Therapeutics has reported EBITDA for 7 years, with the latest figure at -$19.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 28.36% year-over-year to -$19.3 million; the trailing twelve-month figure through Mar 2026 stood at -$83.0 million (up 21.45% YoY), and the FY2025 full-year result was -$90.6 million, up 18.35% from the prior year.
• EBITDA for Q1 2026 stood at -$19.3 million, up from -$20.2 million in the prior quarter.
• The five-year high for EBITDA was -$19.3 million in Q1 2026, with the low at -$33.5 million in Q2 2023.
• Average EBITDA over 5 years is -$27.6 million, with a median of -$29.1 million recorded in 2023.
• Year-over-year, EBITDA plunged 140.85% in 2022 and advanced 28.36% in 2026.
• Tracing TNYA's EBITDA over 5 years: stood at -$33.1 million in 2022, then advanced by 10.1% to -$29.8 million in 2023, then advanced by 19.8% to -$23.9 million in 2024, then grew by 15.53% to -$20.2 million in 2025, then increased by 4.48% to -$19.3 million in 2026.
• The last three EBITDA figures came in at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.

Peer Comparison